As he put it himself, Medivir AB CEO Lars Adlersson had "two reasons to celebrate" Tuesday. The drug discovery company he leads had just signed its largest deal ever, a pact potentially worth €122 million with Boehringer Ingelheim GmbH to develop its candidate HIV drug MIV-310. It was also his 39th birthday. (BioWorld International)